Helus Pharma reports APPROACH Phase 3 enrollment past 86% and launches $50M offering

Cybin Inc. (d/b/a Helus Pharma) (HELP) — Cybin, now operating as Helus Pharma, said enrollment in its APPROACH Phase 3 trial of HLP003, a Breakthrough Therapy-designated deuterated psilocin analog for adjunctive major depressive disorder, had surpassed 86%, keeping topline data on track for Q4 2026.

Alongside the update the company announced a US$50 million underwritten offering to fund the program and a second Phase 3 study, EMBRACE. The progress and financing advance one of the sector's most closely watched late-stage psilocybin-based programs.

Source: globenewswire.com

For the rest of that week's sector news, read our week in review.